Compare Gilead Sciences, Inc. (GILD) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Prudential PLC — how do they compare? Gilead Sciences, Inc. trades at $135 (market cap $164.99B), while Prudential PLC trades at $27.67 (market cap $34.98B). The key difference: Gilead Sciences, Inc. is far larger — about 4.7× Prudential PLC's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.47%). Which is the better fit depends on your goals.
| GILD | PUK | |
|---|---|---|
Market Cap | $164.99B | $34.98B |
Sector | Health | Financials |
52-Week High | $155.80 | $33.61 |
52-Week Low | $110.56 | $24.98 |
Enterprise Value | $188.06B | $36.41B |
Dividend Yield | 2.47% | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Prudential Financial (PUK) trades at $28.28, up 1.43% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates strong fundamentals with Q2 2025 and Q4 2025 earnings beats, robust 14.52% net income margin, and improving cash flow trends. Recent news highlights China regulatory concerns impacting Asian-focused insurers, though Prudential reported solid Q2 2026 results with $985 million net income.
The stock presents value characteristics with a low P/E of 9.21, supported by analyst consensus leaning bullish (50% buy ratings). Key risks include China regulatory exposure and competitive pressures in Asian markets. Upside potential exists if the company successfully executes its capital-light strategy and navigates geopolitical challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
